SCHEMBL5333725

SCHEMBL5333725

N#Cc1ccc(S(=O)(=O)N[C]=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.56
IDO1 P14902 3/20 0.51
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
KDM1A O60341 1/20 0.47
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HSD11B1 P28845 1/20 0.45
MMP1 P03956 2/20 0.44
MMP2 P08253 2/20 0.44
MMP3 P08254 2/20 0.44
MMP7 P09237 2/20 0.44
MMP9 P14780 2/20 0.44
MMP13 P45452 2/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13590961 0.81 CYP19A1 (0.61) CYP19A1IDO1CA1CA2CA12
SCHEMBL19787562 0.79 CYP19A1 (0.59) CYP19A1IDO1CA1CA2CA12
SCHEMBL2495472 0.78 CYP19A1 (0.58) CYP19A1IDO1CA1CA2CA12
SCHEMBL422400 0.78 CYP19A1 (0.58) CYP19A1IDO1CA1CA2CA12
SCHEMBL20256301 0.78 CYP19A1 (0.58) CYP19A1IDO1CA1CA2CA12
SCHEMBL4613144 0.78 CYP19A1 (0.58) CYP19A1IDO1CA1CA2CA12
SCHEMBL9245490 0.78 CYP19A1 (0.58) CYP19A1IDO1CA1CA2CA12
SCHEMBL21800158 0.76 CYP19A1 (0.56) CYP19A1IDO1CA1CA2CA12
SCHEMBL78504 0.75 GAA (0.59) CA1CA2CA12CA9KMT2A
SCHEMBL423687 0.75 CA2 (0.57) CYP19A1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 US claimed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 EP claimed
US-7309718-B2 Dibenzocycloheptene compound UBE INDUSTRIES, LTD. (JP) 2007-12-18 US disclosed
US-20040180884-A1 Dibenzocycloheptene compound UBE INDUSTRIES, LTD. (JP) 2004-09-16 US disclosed
EP-1408033-A1 DIBENZOCYCLOHEPTENE COMPOUND Ube Industries, Ltd. (JP) 2004-04-14 EP disclosed
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 US disclosed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180884-A1 Dibenzocycloheptene compound LTB4R2, LTA4H, LTC4S CYP19A1 842/4885IDO1 312/4885CA1 1141/4885
US-20030216571-A1 Antiallergens; antiinflammatory agents CYSLTR2, CYSLTR1, LTC4S CYP19A1 1687/4885IDO1 42/4885CA1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.